Mino-Kenudson Mari, Ban Shinichi, Ohana Masaya, Puricelli William, Deshpande Vikram, Shimizu Michio, Nishioka Norman S, Lauwers Gregory Y
Department of Pathology, Gastrointestinal Pathology Service, Massachusetts General Hospital, Boston, MA 02114-2696, USA.
Am J Surg Pathol. 2007 Mar;31(3):403-9. doi: 10.1097/01.pas.0000213407.03064.37.
The restoration of squamous epithelium after photodynamic therapy (PDT) for Barrett esophagus (BE) and its related neoplasms has been noted. It may result in the development of buried neoplasms and/or BE underneath restored squamous epithelium which maintain their potential for malignant transformation. The purpose of this study was to evaluate the prevalence, endoscopic, and histologic characteristics and also response to further treatment of buried neoplastic epithelium developing after PDT. Fifty-two BE patients with high-grade dysplasia (n=19), intramucosal adenocarcinoma (n=28), and invasive adenocarcinoma (n=5) were treated with porfimer PDT. Buried neoplasms completely covered by squamous epithelium were seen in 1 patient before and in 13 patients after PDT. Their prevalence was 0.6% and 7.4% of pre and post-PDT biopsy levels positive for neoplasia (P=0.001). Buried neoplasms, representing the highest grade of residual neoplasm, were noted in a series of 11 post-PDT endoscopies (7.1% of 155 post-PDT endoscopies with neoplastic diagnoses) of 8 patients. Their occurrence after PDT was neither associated with the length of BE, the diffuseness of neoplasms nor the presence of buried lesions before treatment. There was no prevalent location for these lesions in relation to the original segment of BE, although the majority of both surface and buried neoplasms were found in the prior neoplastic sites. Patients with buried neoplasms responded to further treatment similarly to those with only surface neoplasms (8 of 13 vs. 17 of 24) (P=0.33). In conclusion, buried neoplasms are not uncommon after PDT. Thorough endoscopic surveillance with extensive biopsies, especially of the sites previously positive for neoplasia is important to avoid overlooking buried neoplasms that may progress.
光动力疗法(PDT)治疗巴雷特食管(BE)及其相关肿瘤后鳞状上皮的恢复已被注意到。这可能导致在恢复的鳞状上皮下出现隐匿性肿瘤和/或BE,它们仍具有恶性转化的潜能。本研究的目的是评估PDT后发生的隐匿性肿瘤上皮的患病率、内镜和组织学特征,以及对进一步治疗的反应。52例BE患者,其中高级别异型增生(n = 19)、黏膜内腺癌(n = 28)和浸润性腺癌(n = 5)接受了卟吩姆钠PDT治疗。PDT前1例患者和PDT后13例患者可见被鳞状上皮完全覆盖的隐匿性肿瘤。它们在肿瘤活检阳性的PDT前和PDT后水平中所占比例分别为0.6%和7.4%(P = 0.001)。在8例患者的11次PDT后内镜检查(155次有肿瘤诊断的PDT后内镜检查中的7.1%)中发现了代表最高级残余肿瘤的隐匿性肿瘤。PDT后它们的发生与BE的长度、肿瘤的弥漫性或治疗前隐匿性病变的存在均无关。尽管大多数表面和隐匿性肿瘤都位于先前的肿瘤部位,但这些病变在与BE原始节段相关的位置上并无普遍规律。隐匿性肿瘤患者对进一步治疗的反应与仅患有表面肿瘤的患者相似(13例中的8例对24例中的17例)(P = 0.33)。总之,PDT后隐匿性肿瘤并不少见。进行全面的内镜监测并广泛活检,尤其是对先前肿瘤阳性的部位进行活检,对于避免忽视可能进展的隐匿性肿瘤很重要。